Restoring vancomycin activity against resistant Enterococcus faecalis using a transcription factor decoy as a vanA operon-inhibitor
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Loai M Abdelall und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Administration of Factories Inspection, Central Administration of Operations, Egyptian Drug Authority, Giza 12654, Egypt. Hauptthemen laut MEDLINE: Enterococcus faecalis, Microbial Sensitivity Tests, Vancomycin, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Background
Vancomycin-resistant enterococci (VRE) represent a public health threat due to the few available treatments. Such alarm has triggered worldwide initiatives to develop effective antimicrobial compounds and novel delivery and therapeutic strategies. vanA operon is responsible for most cases of acquired vancomycin resistance in enterococci.
Objectives
Development of a transcription factor decoy (TFD) system as a vanA gene transcription-inhibitor.
Methods
Vancomycin MIC was determined in the presence of TFD-lipoplexes. Additionally, the effect of TFD-lipoplexes on the expression level of the vanA gene and the growth pattern of E. faecalis was evaluated. The haemolytic activity of the developed TFD-lipoplexes and their cytotoxicity were examined. TFD-lipoplexes efficiency in treating vancomycin-resistant E. faecalis (VREF) infection was tested in vivo using a systemic mice infection model.
Results
A reduction in vancomycin MIC against VRE from 256 mg/L (resistant) to 16 mg/L (intermediate susceptible), in the presence of TFD-lipoplexes, was recorded. The developed TFD-lipoplexes lacked any effect on E. faecalis growth and significantly reduced the transcription level of the vanA gene by about 3-fold. In an initial evaluation of the safety of TFD-lipoplexes, they were found not to be overtly haemolytic to human blood or cytotoxic to human skin fibroblast cells. The co-administration of TFD-lipoplexes and vancomycin efficiently eradicated VREF infection in vivo.
Conclusions
The developed TFD-lipoplexes successfully restored vancomycin activity against VREF. They offer a safe effective unconventional therapy against this stubborn organism and present a revolution in gene therapy that can be applied to other resistance-encoding genes in various organisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Administration of Factories Inspection, Central Administration of Operations, Egyptian Drug Authority, Giza 12654, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Zitieren
APA
Abdelall, L. M., Nagy, Y. I., & Kashef, M. T. (2024). Restoring vancomycin activity against resistant Enterococcus faecalis using a transcription factor decoy as a vanA operon-inhibitor. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae320
Vancouver
Abdelall LM, Nagy YI, Kashef MT. Restoring vancomycin activity against resistant Enterococcus faecalis using a transcription factor decoy as a vanA operon-inhibitor. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae320
BibTeX
@article{Abdelall2024,
author = {Abdelall, Loai M and Nagy, Yosra Ibrahim and Kashef, Mona T},
title = {Restoring vancomycin activity against resistant Enterococcus faecalis using a transcription factor decoy as a vanA operon-inhibitor},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae320}
}
EUVIMED